Preliminary phase I clinical data suggest that most of these IDH1 or 2 inhibitors are well tolerated, are associated with lower cellular 2-HG levels, and have potential antitumor activity, especially in IDH1-mutated gliomas. The gene discussed is IDH1; the disease is glioma.